Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eli Lilly CEO John Lechleiter Rules Out Mega-merger Or Major Push Into Generics, Outlines Strategy Aimed At China's 21st Century Rise In An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Eli Lilly's chief executive officer, John Lechleiter, recently discussed with PharmAsia News' China bureau the Indianapolis-headquartered outfit's strategy to benefit from the rapid rise of China's economy and scientific capabilities while also spelling out that the company would not seek to engineer any mega-merger ahead. The organic chemist who heads Lilly suggested in a keynote talk in Shanghai that Chinese scientists would increasingly help shape "the century of human medicine" if the government strengthens the intellectual property regime in order to unleash innovation (PharmAsia News, April 02, 2010), and expanded on those ideas in a follow-up interview.

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts